LDE Stock Overview
Operates as an integrated contract development and manufacturing organization in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Lifecore Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.00 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$3.38 |
| Beta | 0.94 |
| 11 Month Change | 32.16% |
| 3 Month Change | 21.46% |
| 1 Year Change | -9.77% |
| 33 Year Change | -27.71% |
| 5 Year Change | n/a |
| Change since IPO | 20.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDE | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -5.2% | -0.5% |
| 1Y | -9.8% | 2.8% | 8.3% |
Return vs Industry: LDE underperformed the German Life Sciences industry which returned 2.8% over the past year.
Return vs Market: LDE underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| LDE volatility | |
|---|---|
| LDE Average Weekly Movement | 12.5% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LDE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LDE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 524 | Paul Josephs | www.lifecore.com |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
Lifecore Biomedical, Inc. Fundamentals Summary
| LDE fundamental statistics | |
|---|---|
| Market cap | €223.88m |
| Earnings (TTM) | €5.42m |
| Revenue (TTM) | €122.01m |
41.5x
P/E Ratio1.8x
P/S RatioIs LDE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDE income statement (TTM) | |
|---|---|
| Revenue | US$128.44m |
| Cost of Revenue | US$83.94m |
| Gross Profit | US$44.51m |
| Other Expenses | US$38.80m |
| Earnings | US$5.71m |
Last Reported Earnings
Aug 25, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 34.65% |
| Net Profit Margin | 4.45% |
| Debt/Equity Ratio | 323.8% |
How did LDE perform over the long term?
See historical performance and comparison